Journal of Oral Medicine and Pain

Korean Academy of Orofacial Pain and Oral Medicine (대한안면통증구강내과학회)
권호 표지
DOI QR코드

DOI QR Code

Drug-induced Gingival Overgrowth Related to Sirolimus and Felodipine

  • Park, Youn-Jung (Department of Orofacial Pain and Oral Medicine, Dental Hospital, Yonsei University College of Dentisty) ;
  • Lee, Joo-Hee (Department of Orofacial Pain and Oral Medicine, Dental Hospital, Yonsei University College of Dentisty) ;
  • Kim, Young-Gun (Department of Orofacial Pain and Oral Medicine, Dental Hospital, Yonsei University College of Dentisty) ;
  • Kwon, Jeong-Seung (Department of Orofacial Pain and Oral Medicine, Dental Hospital, Yonsei University College of Dentisty) ;
  • Ahn, Hyung-Joon (Department of Orofacial Pain and Oral Medicine, Dental Hospital, Yonsei University College of Dentisty) ;
  • Choi, Jong-Hoon (Department of Orofacial Pain and Oral Medicine, Dental Hospital, Yonsei University College of Dentisty)
  • Received : 2017.03.16
  • Accepted : 2017.03.24
  • Published : 2017.03.30
Download PDF
⟨ Previous Next ⟩

Abstract

Drug-induced gingival overgrowth (DIGO) is an adverse drug reaction mainly described with three types of commonly prescribed drugs, namely, calcium channel blockers (CCBs) (nifedipine, diltiazem, and verapamil), anti-convulsants (phenytoin), and immunosuppressive agents (cyclosporine). Numerous reports have associated gingival overgrowth with the newer generation of immunosuppressive agents (tacrolimus, sirolimus, and everolimus), and CCBs (amlodipine, felodipine, nicardipine, and manidipine). Especially, patients concomitantly medicated with an immunosuppressive agent and CCB have a higher DIGO chance. Dentists need to be aware of drugs that induce gingival overgrowth, the possibility of DIGO, and risk factors, and also prevent the progression of DIGO by early detection of DIGO, consultation about the drug change, and the maintenance of strict dental hygiene regimes.

Keywords

References

  1. Brown RS, Arany PR. Mechanism of drug-induced gingival overgrowth revisited: a unifying hypothesis. Oral Dis 2015;21:e51-e61. https://doi.org/10.1111/odi.12264
  2. Dongari-Bagtzoglou A; Research, Science and Therapy Committee, American Academy of Periodontology. Drug-associated gingival enlargement. J Periodontol 2004;75:1424-1431. https://doi.org/10.1902/jop.2004.75.10.1424
  3. Livada R, Shiloah J. Calcium channel blocker-induced gingival enlargement. J Hum Hypertens 2014;28:10-14. https://doi.org/10.1038/jhh.2013.47
  4. Cota LO, Aquino DR, Franco GC, Cortelli JR, Cortelli SC, Costa FO. Gingival overgrowth in subjects under immunosuppressive regimens based on cyclosporine, tacrolimus, or sirolimus. J Clin Periodontol 2010;37:894-902. https://doi.org/10.1111/j.1600-051X.2010.01601.x
  5. Perez-Barrio S, Gonzalez Hermosa MR, Diaz-Perez JL. Gingival hyperplasia secondary to everolimus therapy. Actas Dermosifil-iogr 2010;101:372-373. https://doi.org/10.1016/j.ad.2009.11.011
  6. Ellis JS, Seymour RA, Steele JG, Robertson P, Butler TJ, Thomason JM. Prevalence of gingival overgrowth induced by calcium channel blockers: a community-based study. J Periodontol 1999;70:63-67. https://doi.org/10.1902/jop.1999.70.1.63
  7. Magee CC, Pascual M. Update in renal transplantation. Arch Intern Med 2004;164:1373-1388. https://doi.org/10.1001/archinte.164.13.1373
  8. Danovitch GM. Immunosuppressant-induced metabolic toxicities. Transplant Rev 2000;14:65-81. https://doi.org/10.1053/tr.2000.5377
  9. Watson CJE. Sirolimus (rapamycin) in clinical transplantation. Transplant Rev 2001;15:165-177. https://doi.org/10.1016/S0955-470X(01)80016-1
  10. Tyldesley WR, Rotter E. Gingival hyperplasia induced by cyclosporin-A. Br Dent J 1984;157:305-309. https://doi.org/10.1038/sj.bdj.4805474
  11. Cota LO, Oliveira AP, Costa JE, Cortelli SC, Costa FO. Gingival status of Brazilian renal transplant recipients under sirolimusbased regimens. J Periodontol 2008;79:2060-2068. https://doi.org/10.1902/jop.2008.080194
  12. Lima RB, Benini V, Sens YA. Gingival overgrowth in renal transplant recipients: a study concerning prevalence, severity, periodontal, and predisposing factors. Transplant Proc 2008;40:1425-1428. https://doi.org/10.1016/j.transproceed.2008.01.071
  13. Camargo PM, Melnick PR, Pirih FQ, Lagos R, Takei HH. Treatment of drug-induced gingival enlargement: aesthetic and functional considerations. Periodontol 2000 2001;27:131-138. https://doi.org/10.1034/j.1600-0757.2001.027001131.x
  14. Pilatti GL, Sampaio JE. The influence of chlorhexidine on the severity of cyclosporin A-induced gingival overgrowth. J Periodontol 1997;68:900-904. https://doi.org/10.1902/jop.1997.68.9.900
  15. Arya R, Gulati S, Kabra M, Sahu JK, Kalra V. Folic acid supplementation prevents phenytoin-induced gingival overgrowth in children. Neurology 2011;76:1338-1343. https://doi.org/10.1212/WNL.0b013e3182152844